Go to Health Care Provider version
| Diagnosis | High Grade Glioma, Ewing sarcoma, Rhabdomyosarcoma | Study Status | Completed |
| Phase | I/II |
| Age | Child, Adult - (2 Years to 21 Years) | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | Oral hard tablets or suspension
|
| Last Posted Update | 2022-02-14 |
| ClinicalTrials.gov # | NCT03245151 |
International Sponsor
Eisai Inc.Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Daniel Morgenstern
IWK Health Centre - Dr. Craig Erker
Montreal Children's Hospital - Dr. Sharon Abish
Centres
Medical contact
Dr. Craig Erker
Dr. Conrad Fernandez
Dr. Ketan Kulkarni
Social worker/patient navigator contact
Rhonda Brophy
Clinical research contact
Tina Bocking
Medical contact
Clinical Research Unit
Social worker/patient navigator contact
Clinical Research Unit
Clinical research contact
Stephanie Badour
Study Description
This is a study of two medications taken by mouth, called lenvatinib and everolimus. Lenvatinib blocks cell proteins and signals directed at blood vessels that help the cancer to survive. Everolimus is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. It is called an mTOR inhibitor.
The phase 1 of this study has been completed, and now the phase 2 is on-going to understand the anti-cancer activity of those two medications taken together in patients with Ewing sarcoma, rhabdomyosarcoma or high grade glioma that has come back (relapsed) or is refractory to treatment.
Inclusion Criteria
- Age from 2 years to 21 years
- Diagnosis of Ewing sarcoma, rhabdomyosarcoma or high grade glioma that has come back (relapsed) or is refractory to treatment
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
